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ABSTRACT
Tuberculosis, caused by Mycobacterium tuberculo-
sis, responsible for ∼1.5 million fatalities in 2018,
is the deadliest infectious disease. Global spread
of multidrug resistant strains is a public health
threat, requiring new treatments. Aminoacyl-tRNA
synthetases are plausible candidates as potential
drug targets, because they play an essential role
in translating the DNA code into protein sequence
by attaching a specific amino acid to their cog-
nate tRNAs. We report structures of M. tuberculo-
sis Phe-tRNA synthetase complexed with an unmod-
ified tRNAPhe transcript and either L-Phe or a non-
hydrolyzable phenylalanine adenylate analog. High-
resolution models reveal details of two modes of
tRNA interaction with the enzyme: an initial recogni-
tion via indirect readout of anticodon stem-loop and
aminoacylation ready state involving interactions of
the 3′ end of tRNAPhe with the adenylate site. For
the first time, we observe the protein gate control-
ling access to the active site and detailed geome-
try of the acyl donor and tRNA acceptor consistent
with accepted mechanism. We biochemically vali-
dated the inhibitory potency of the adenylate analog
and provide the most complete view of the Phe-tRNA
synthetase/tRNAPhe system to date. The presented
topography of amino adenylate-binding and editing
sites at different stages of tRNA binding to the en-
zyme provide insights for the rational design of anti-
tuberculosis drugs.
INTRODUCTION
With ∼1.5 million people killed by tuberculosis (TB) in
2018, Mycobacterium tuberculosis remains the deadliest
pathogen worldwide (1) and the leading cause of morbid-
ity and mortality among HIV-infected patients. It is esti-
mated that one third of the world’s population is at risk of
developing active TB disease, especially in low- and middle-
income countries. Extensively drug-resistant TB (XDR-TB)
and multidrug-resistant TB (MDR-TB) constitute a grow-
ing global public health threat (2). The existing TB multi-
drug treatments are long, particularly for XDR-TB and
MDR-TB infections. Discovery of drugs with novel mech-
anisms of action is critical for defeating the existing drug
resistant strains and shortening the TB treatment (3).
Lynezolid, an FDA-approved antibiotic, and several
other anti-TB compounds presently tested in clinical tri-
als, target protein translation, an essential process in all cel-
lular organisms (4,5). One of the crucial steps in this pro-
cess is carried out by aminoacyl-tRNA synthetases (aaRS)
that catalyze the attachment of a specific amino acid to the
cognate tRNA (6,7). Some aaRSs are equipped with proof-
reading mechanisms to ensure correct pairing of amino acid
and tRNA. The synthesis of aminoacyl-tRNA is accom-
plished by a two-step reaction. Formation of the aminoacyl-
adenylate from an amino acid and ATP, sometimes carried
out in a tRNA-dependent manner (8), is followed by liga-
tion of the aminoacyl group to the 3′-terminal adenosine of
tRNA.
FRS, which is specific for L-phenylalanine and tRNAPhe,
has been studied extensively biochemically, structurally and
computationally for the past 50 years (9–12). Several FRS
structures at moderate resolutions are available in the Pro-
tein Data Bank (PDB) (Table 1). All of them belong to the
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class IIC aaRS and show similarity to class IIA SRS as well
as more distant homology to ancient GRS and ARS class
IID (6,7). Typically, class II aaRSs aminoacylate tRNA on
3′OH of ribose, but FRS does so on 2′OH. The bacterial, ar-
chaeal and human cytoplasmic enzymes consist of  (PheS)
and  subunits (PheT), that via domain swapping, form
highly intertwined ()2 heterotetramers (11,13–17). The
 subunit recognizes L-Phe and 3′ terminal adenosine of
tRNA and carries out key catalytic activities (18). The 
subunit recognizes tRNAPhe and provides an editing func-
tion assuring that only the L-Phe is attached to tRNAPhe
(19).
FRS, an essential component of the protein synthesis ap-
paratus, has been recognized as a high-priority antimicro-
bial drug target (19,20). Phenyl-thiazolylurea-sulfonamides
are potent inhibitors of both Gram-negative and Gram-
positive bacterial FRS orthologs (9). Ethanolamine deriva-
tives inhibit FRS from Staphylococcus aureus (21), gossypol
blocks Pseudomonas aeruginosa and Streptococcus pneu-
moniae (22). Some natural products are able to act on
M. tuberculosis FRS (MtFRS) (23). However, no FRS
inhibitor has reached advanced therapeutic development
stages.
Here, to address a major knowledge gap in M. tuberculo-
sis protein synthesis, we present four crystal structures of
MtFRS in complex with a full-length unmodified M. tu-
berculosis tRNAPhe transcript (abbreviated as MttRNAPhe
throughout the text). For the first time we show for FRS
that the tRNA binding and recognition are occurring in two
distinct stages. The ‘initial tRNA recognition’ state was de-
termined either with bound L-Phe (in two crystal forms), or
with an inhibitor – a nonhydrolyzable phenylalanine adeny-
late analog 5′-O-(N-phenylalanyl)sulfamoyl-adenosine (F-
AMS). The ‘aminoacylation ready’ state, in which tRNA
is predisposed for accepting an activated amino acid, was
determined in a complex with F-AMS. These structures of-
fer the most complete picture of the FRS-tRNAPhe complex
to date and combined with biochemical characterization of
the enzyme and F-AMS binding, provide insights that are
essential for rational structure-based drug design of selec-
tive inhibitors of MtFRS.
MATERIAL AND METHODS
Cloning and expression of M. tuberculosis FRS subunits,
PheS and PheT
The pheS and pheT genes were amplified from genomic






ACC. PCR products were purified and treated with T4
polymerase in presence of dCTP according to Kim et al.
(24). PheS gene was cloned to pMCSG53, while pheT
was cloned to pMCSG120. Both vectors contain identical
cloning sites. pMCSG53 carries ampicillin resistance and
ColE1 origin of replication. pMCSG120 retains resistance
to kanamycin and has RSF origin of replication. In the final
construct the PheS sequence is amended on N-terminus
with His6 affinity tag and Tobacco Etch Virus (TEV)
protease cleavage site.
Escherichia coli BL21-Gold (DE3) was co-transformed
with plasmids PheS-pMCSG53 and PheT-pMCSG120 and
grown overnight in LB medium supplemented with 40 mM
K2HPO4 at 37◦C/220 rpm with selection against ampi-
cillin (150 g/ml) and kanamycin (100 g/ml). The fol-
lowing morning the culture was diluted 1:100 into LB me-
dia with the same concentration of antibiotics and grown
at 37◦C/190 rpm till OD600 reached about 1.0 followed
by cooling of media to about 20◦C. At this point the
media were supplemented with 0.25 mM IPTG, 40 mM
K2HPO4 and 0.5% glucose. The culture was grown for an-
other 20 h at 18◦C/190 rpm followed by cells harvest and
resuspension in buffer A (50 mM HEPES/NaOH, pH 8.0,
0.5 M NaCl, 20 mM imidazole, pH 8.0, 5% glycerol, 1
mM TCEP). The cell suspension was frozen and stored at
−80◦C.
Synthesis of a full-length unmodified M. tuberculosis
tRNAPhe transcript (GAA)
The isoacceptor tRNAPhe(GAA) recognizing specifi-
cally UUC codon and its truncated derivatives lack-
ing the 3′-terminal adenosines were prepared as
described previously by Sherlin et al. (25). Oligonu-







mU and mG represent the 2′-O-methyl nucleotides used
to reduce the proportion of runover transcripts and in-
crease their yields. The underlined portions represent the
overlapped segment and bold type indicates the T7 RNA
polymerase promoter. To synthesize these transcripts, 10
g/ml duplex DNA template in a solution containing
200 mM HEPES/KOH (pH 7.5), 30 mM MgCl2, 2 mM
spermidine, 40 mM DTT, 6 mM each ATP, CTP, GTP and
UTP was incubated with 100 g/ml T7 RNA polymerase, 5
U/ml inorganic pyrophosphatase, 50 U/ml SUPERase•In
RNase Inhibitor (Invitrogen) in an 8 ml reaction for 5
h at 37◦C. The procedure yields full length MttRNAPhe
transcript. DNA template was removed by addition of 50
U/ml RQ1 RNase-free DNase (Promega) and incubation
for 1 h at 37◦C, followed by phenol-chloroform extraction.
The tRNA was recovered from the aqueous phase by
ethanol precipitation and then fractionated on DE-52
(Whatman) column as described before (25). Integrity of
the purified tRNA was confirmed by electrophoresis on
a 10% denaturing polyacrylamide gel. The tRNA was
dialyzed into 20 mM HEPES/KOH (pH 7.5), 150 mM KCl
and 5 mM MgCl2 buffer prior to further use. The fraction
of tRNA capable of being aminoacylated by MtFRS was
determined by assays under conditions giving maximal
amino acid incorporation (approximately ten-fold molar
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Table 1. FRS structures in the Protein Data Bank






1B70 T. thermophilus (/)2 complex with L-Phe in  2.70 39/34 Reshetnikova et al. (18)
1B7Y T. thermophilus (/)2 complex with
adenosine-5′-[phenylalaninol-phosphate] in 
2.50 Reshetnikova et al. (18)
1EIY T. thermophilus (/)2 complex with tRNAPhe 3.30 Goldur et al. (55)
1JJC T. thermophilus (/)2 complex with
adenosine-5′-[phenylalaninyl-phosphate] in 
2.60 Fishman et al. (66)
1PYS T. thermophilus (/)2 complex 2.90 Mosyak et al. (13)
2AKW T. thermophilus (/)2 complex with p-Cl-Phe in  2.80 Kotik-Kogan et al. (19)
2ALY T. thermophilus (/)2 complex with
5′-O-[N-L-tyrosyl)sulfamoyl]adenosine in 
2.60 Kotik-Kogan et al. (19)
2AMC T. thermophilus (/)2 complex with L-Tyr in  2.70 Kotik-Kogan et al. (19)
2IY5 T. thermophilus (/)2 complex with tRNAPhe and
adenosine-5′-[phenylalaninol-phosphate] in 
3.10 Moor et al. (67)
3HFZ T. thermophilus (/)2 complex with m-L-Tyr in  2.90 Klipcan et al. (68)
3TEH T. thermophilus (/)2 complex with 3,4-dihydroxyphenylalanine in  2.85 Moor et al. (69)
4TVA T. thermophilus (/)2 complex with puromycin in  and L-Phe in  2.60 Tworowski et al. (70)
2RHQ S. haemolyticus (/)2 complex with 1-{3-[(4-pyridin-2-ylpiperazin-1-
yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea in , 6
mutations in 
2.20 41/31 Evdokimov et al. (15)
2RHS S. haemolyticus (/)2 complex with 1-{3-[(4-pyridin-2-ylpiperazin-1-
yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea in , 5
mutations in 
2.20 Evdokimov et al. (15)
3PCO E. coli (/)2 complex with L-Phe and AMP in  3.02 45/31 Mermershtain et al. (17)
4P71 P. aeruginosa (/)2 complex 2.79 43/32 Abibi et al. (71)
4P72 P. aeruginosa (/)2 complex with compound 2-{3-[(4-chloropyridin-
2-yl)amino]phenoxy}-N-methylacetamide in 
2.62 Abibi et al. (71)
4P73 P. aeruginosa (/)2 complex with compound 1-{3-[(4-pyridin-
2-ylpiperazin-1-yl)sulfonyl]phenyl}-
3-(1,3-thiazol-2-yl)urea in 
3.03 Abibi et al. (71)




2.70 Abibi et al. (71)
4P75 P. aeruginosa (/)2 complex with compound
3-(3-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazole
in 
2.96 Abibi et al. (71)
3ICA P. gingivalis  subunit fragment 2.44 36/27 Fan et al., unpublished
3IG2 B. fragilis  subunit fragment 2.09 38/28 Stein et al., unpublished
2CXI P. horikoshii  subunit fragment, 9 mutations 1.94 19/13 Sasaki et al. (14)
3CMQ H. sapiens Mitochondrial monomer with
adenosine-5′-[phenylalaninyl-phosphate]
2.20 27, 28b Klipcan et al. (72)
3HFV H. sapiens Mitochondrial monomer with m-L-Tyr 2.60 Klipcan et al. (68)
3TEG H. sapiens Mitochondrial monomer with
3,4-dihydroxyphenylalanine
2.20 Moor et al. (69)
3TUP H. sapiens Mitochondrial monomer with TttRNAPhe 3.05 Klipcan et al. (11)
5MGH H. sapiens Mitochondrial monomer, point mutant with L-Phe 1.87 Kartvelishvili et al. (73)
5MGU H. sapiens Mitochondrial monomer, point mutant with L-Phe 1.89 Kartvelishvili et al. (73)
5MGW H. sapiens Mitochondrial monomer, point. mutant with L-Phe 1.46 Kartvelishvili et al. (73)
5MGV H. sapiens Mitochondrial monomer, point mutant 2.05 Kartvelishvili et al. (73)
3L4G H. sapiens Cytosolic (/)2 complex with L-Phe in  3.30 34/18 Finarov et al. (16)
aAs determined by Emboss Needle (74).
bThe numbers correspond to MtFRS  subunit residues 108–341 aligned with human mitochondrial FRS residues 82–347 and MtFRS  subunit residues
739–831 with 360–451).
FRS purification and crystallization
Frozen cells were thawed and sonicated (5 min total time,
130 W power output) and spun at 30 000 × g at 4◦C for 1
h. The initial Ni2+ affinity purification step was performed
using a 2.5-cm × 10-cm Flex-Column connected to a Van-
Man vacuum manifold (Promega) (26). Briefly: supernatant
was loaded on 3 ml Ni2+ Sepharose (GE Healthcare Life
Sciences) equilibrated with buffer A and mixed thoroughly
with the resin. Vacuum of 15 psi was used to speed re-
moval of supernatant as well as wash out of unbound pro-
teins (150 ml buffer A supplemented to 50 mM imida-
zole). The FRS complex was eluted with 15 ml buffer A
supplemented with 500 mM imidazole, pH 8.0. The eluate
was concentrated to about 2 ml and loaded on a Superdex
200 16/70 size exclusion column (GE Healthcare Life Sci-
ences) equilibrated with buffer A. Fractions containing the
FRS complex were collected, and buffer A was replaced
with crystallization buffer (20 mM HEPES/NaOH, pH
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tors (Millipore) followed by overnight incubation at 4◦C
with MttRNAPhe. The molar ratio of tRNAPhe to FRS het-
erotetramer ()2 was 2:1. Protein-tRNA complex was con-
centrated to ∼20 mg/ml. The ligands were added at mo-
lar ratios 4:1. Crystallization experiments were performed
at 16◦C using the sitting-drop vapor-diffusion method in
96-well CrystalQuick plates (Greiner Bio-One, Monroe,
NC) with the help of the Mosquito liquid dispenser (TTP
LabTech, Cambridge, MA, USA). Crystallizations trials
were performed using protein-tRNA to matrix ratio 1:1
(800 nl drops). Crystallization and cryocooling conditions
are given in Table 2.
X-ray data collection, structure determination, refinement
and analysis
Prior to data collection at 100 K, all cryoprotected crystals
were flash-cooled in liquid nitrogen. The X-ray diffraction
experiments were carried out at the Structural Biology Cen-
ter 19-ID beamline at the Advanced Photon Source, Ar-
gonne National Laboratory. The diffraction images were
recorded on the PILATUS3 × 6M detector. The data
sets were processed with the HKL3000 suite (27). Inten-
sities were converted to structure factor amplitudes in the
Ctruncate program (28,29) from the CCP4 package (30).
The data collection and processing statistics are given in
Table 2.
The initial FRS structure was solved by molecular re-
placement using monomeric units of E. coli FRS as a search
template (PDB id 3PCO) against the dataset from low res-
olution apo crystals of MtFRS. The FRSt/F1 structure
was determined using the partially built apo model. The
search of tRNA molecule from T. thermophilus FRS com-
plex structure (PDB id 1EIY) failed so the entire nucleic
acid molecule has been built manually from scratch. The
subsequent structures were determined using the FRSt/F1
model. The structures were refined by manual corrections in
Coot (31) and crystallographic refinement in Refmac (32)
and Phenix (33). The electron density in composite omit
map for protein, tRNA, L-Phe, F-AMS is excellent (Sup-
plementary Figure S1). The refinement statistics are given in
Table 2. The structures were analyzed using Chimera (34),
SNAP (for protein-RNA interactions, snap.x3DNA.org),
and the RNA-align server (for RNA superposition) (35).
Some of the atoms that appeared to be cations could not be
confidently identified and have been modeled as unknown
atoms UNX. The atomic coordinates and structure fac-
tors have been deposited in the PDB under accession codes
7KA0, 7KAB, 7K9M, 7K98.
Aminoacylation of MttRNAPhe
Purified M. tuberculosis tRNA transcripts lacking the 3′-
terminal adenosine were 32P-labeled with yeast ATP/CTP
tRNA nucleotidyl transferase in the presence of [-32P]ATP
as described in Wower et al. (36). Aminoacylations of the 3′-
32P-labeled MttRNAPhe were carried out in 50 l of 50 mM
HEPES/KOH, pH 7.5, 20 mM KCl, 10 mM MgCl2, 100
g/ml BSA, 5 mM DTT, 4 mM ATP, 0.2 mM L-Phe and
50 nM tRNA transcript. Reactions were initiated by addi-
tion of a purified M. tuberculosis phenylalanyl-tRNA syn-
thetase to final concentration of 0.7 M and incubated for
30 min at 37◦C. The extent of aminoacylation was analyzed
by gel-shift electrophoresis according to Varshney et al.
(37). Prior to electrophoresis, on a 10% acid/7 M urea poly-
acrylamide gel, 10 pmoles of uncharged and aminoacylated
tRNA (Phe-tRNAPhe) were completely digested with 2 U
of RNase T1 (Worthington) in 10 mM sodium acetate (pH
4.5). The amount of radioactivity in the bands correspond-
ing to uncharged and aminoacylated CCACCA oligonu-
cleotides was quantitated by phosphorimaging and/or liq-
uid scintillation counting of the excised strips of the poly-
acrylamide gel.
The value of IC50 was determined at 1.5 M concen-
tration of phenylalanine over a range of inhibitor concen-
tration from zero to 200 nM. According to the Cheng-
Prusoff equation, IC50 values approximate Ki when sub-
strate concentration used in the assay is lower than Km
(38).
Aminoacylation of E. coli and yeast tRNAPhe
Aminoacylation reactions were performed as described
above with the following modifications: 3′-32P-labeled
MttRNAPhe were replaced either by non-radioactive
MttRNAPhe or fully modified E. coli and yeast tRNAPhe
preparations from Sigma. [-32P]ATP from PerkinElmer
was used instead of non-radioactive ATP. All reactions
were quenched in 400 mM sodium acetate (pH 5.2)
with 0.1% SDS. Aliquots were spotted on prewashed
polyethyleneimine-cellulose TLC plates (Macherey and
Nagel) and developed in 100 mM ammonium acetate, 5%
(v/v) acetic acid.
MtFRS inhibition by F-AMS
Aminoacylation assays were carried out by a very sensitive
assay that has been described by Bullock et al. (39). The
assay was performed by 10 min incubation of L-Phe with
purified enzyme in 50 mM HEPES/KOH (pH 7.5), 20 mM
KCl, 10 mM MgCl2, 4 mM ATP/20 M [-32P]ATP, 0.1%
dimethyl sulfoxide in a final volume of 20 l at 37◦C. Km for
L-Phe and Ki were determined by varying concentrations of
amino acid and inhibitor from 0.5 to 25 mM and from 15 to
125 nM, respectively. The concentration of FRS was 6 nM.
The reactions were stopped by adding 2.0 l of the reaction
mixtures to 3.0 l of a solution containing 400 mM sodium
acetate (pH 5.2) and 0.1% SDS. 2.0 l aliquots of this mix-
ture were spotted on dry polyethyleneimine (PEI) cellulose
plates that have been prewashed in water. Phe-[32P]AMP
were separated from [-32P]ATP using 0.1 M ammonium
acetate/5% acetic acid as developing solution, visualized by
autoradiography and quantified by phosphorimaging anal-
ysis.
Synthesis of phenylalanine adenylate analog
5′-O-[N-(phenylalanine)sulfamoyl] adenosine, Phe-AMS,
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Table 2. Data processing and refinement statistics
Data processing





0.2 M Li2SO4, 0.1











30% PEG400, 0.2 M
MgCl2, 0.1 M
HEPES pH 7.5; No
cryoprotectant
Wavelength (Å) 0.9793 0.9793 0.9793 0.9793
Resolution range
(Å)a
2.40–50.00 2.50–30.00 2.50–50.0 2.20–30.0
(2.40–2.44) (2.50–2.54) (2.50–2.54) (2.20–2.24)
Space group C2 C2 C2 P21
Unit cell (Å, ◦) a = 292, b = 110, c
= 128, β = 100
a = 127, b = 110, c
= 148, β = 105
a = 128, b = 110, c
= 147, β = 103
a = 147, b = 65, c =
193, β = 109
Unique reflections
(merged)
155 793 (7677) 68 179 (3404) 68 621 (3274) 173 141 (8263)
Multiplicity 6.4 (5.5) 7.0 (5.9) 6.2 (3.9) 6.4 (6.0)
Completeness (%) 98.9 (98.2) 99.3 (99.4) 99.0 (96.2) 96.9 (93.6)
Mean I/sigma(I) 14.2 (1.78) 17.9 (1.10) 13.8 (1.60) 21.5 (1.56)
Wilson B-factor
(Å2)
32.4 52.5 31.9 45.8
R-mergeb 0.147 (1.207) 0.141 (1.374) 0.171 (0.832) 0.094 (1.223)




2.40–48.00 2.50–29.69 2.50–47.92 2.19–29.85
Reflections
work/test
135 987/7094 66 452/1665 63 320/3264 169 565/3498
Rwork/Rfreed 0.176/0.215 0.187/0.213 0.179/0.215 0.178/0.224
Number of
non-hydrogen atoms
21 651 10 440 10 722 22 017
Macromolecules 20 563 10 237 10 292 21 241
Ligands/solvent 184/904 53/150 108/322 101/675
Amino acid residues 339+835+336+835 336+835 339+834 343+834+343+836
Nucleic acid bases 66+66 66 66 77+77
RMSD(bonds) (Å) 0.003 0.002 0.002 0.007
RMSD(angles) (◦) 0.599 0.478 0.504 0.915
Ramachandran
favorede (%)
96.65 96.39 96.83 96.85
Ramachandran
allowed (%)
3.09 3.26 3.08 3.02
Ramachandran
outliers (%)
0.26 0.34 0.09 0.13
Rotamer outliers
(%)
2.03 1.88 0.98 2.79
Clashscore 3.45 3.93 3.04 2.70
Average B-factor
(Å2)
65.58 99.46 56.72 61.11
macromolecules 66.51 100.05 57.36 61.46
ligands 67.43 92.47 54.38 49.86
solvent 44.14 61.43 36.99 51.67
Number of TLS
groups
39 16 11 34
PDB ID 7KA0 7KAB 7K9M 7K98
aValues in parentheses correspond to the highest resolution shell.
bRmerge = hj|Ihj – <Ih>|/hjIhj, where Ihj is the intensity of observation j of reflection h.
cAs defined by Karplus and Diederichs (75).
dR = h|Fo| – |Fc|/h|Fo| for all reflections, where Fo and Fc are observed and calculated structure factors, respectively. Rfree is calculated analogously
for the test reflections, randomly selected and excluded from the refinement.
eAs defined by Molprobity (76).
RESULTS AND DISCUSSION
tRNAPhe and F-AMS binding
To investigate structure-function relationships in MtFRS,
we have co-expressed PheS () and PheT () subunits
of MtFRS and purified the functional heterotetrameric
complex. In addition, we have prepared MttRNAPhe spe-
cific for the 5′UUC codon. This MttRNAPhe lacks post-
transcriptional modifications. The genus-specific modifica-
tions are unknown but in other organisms tRNAPhe has
been shown to carry varying sets of m1A, ms2i6A, m1C,
m3C, m5C, m1G, m2G, m3G, , acp3U, D, T and wyb-
utosine (41,42). The majority of these modified nucleotides
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tant for codon – anticodon interactions, translational rates,
reading frame maintenance, co-translational protein fold-
ing dynamics and other cellular processes (43,44).
To confirm enzymatic activity of the protein, we
have independently tested both L-Phe adenylation and
tRNA aminoacylation in the presence of three substrates,
MttRNAPhe as well as E. coli and yeast tRNAsPhe.
MttRNAPhe can be almost completely (>99%) charged by
MtFRS with L-Phe (Figure 1). MtFRS can also aminoa-
cylate mature tRNAPhe molecules isolated from E. coli and
yeasts (Figure 1). MtFRS, like all known FRS, is able to ac-
tivate its amino acid substrate in the absence of tRNA (Fig-
ure 1A–C), though the addition of tRNA stimulates this re-
action.
Aminoacyl-sulfamoyl adenosine compounds have been
previously reported as inhibitors of bacterial aaRSs (45–
47). Here, we show strong inhibition of MtFRS by
the non-hydrolyzable phenylalanine adenylate analog, 5′-
O-[N-(phenylalanine)sulfamoyl] adenosine (F-AMS). Ear-
lier studies have demonstrated that aminoacyl-sulfamoyl-
adenosines efficiently inhibit E. coli ERS (Ki 2.8 nM) (45),
murine liver ERS (Ki ∼ 70 nM) (45)), E. coli QRS (Ki 1.3
mM), S. aureus IRS (IC50 4 nM) (47), RRS (IC50 4.5 nM),
HRS (IC50 130 nM) and TRS (IC50 15 nM) (46). Consis-
tent with the earlier studies, F-AMS acts as a competitive
inhibitor with a Ki of 33 nM and IC50 value of ∼36 nM
(Figure 2).
Overall structure of MtFRS
To understand structural basis of aminoacylation reac-
tion and tRNA recognition, we have crystallized MtFRS
with MttRNAPhe and either L-Phe or F-AMS. Four struc-
tures have been determined - two representing different
crystal forms of the MtFRS-MttRNAPhe/L-Phe complex
(MtFRSt/F1, and MtFRSt/F2) and two corresponding to
different forms of the MtFRS-MttRNAPhe/F-AMS com-
plex (MtFRSt/F-AMS1 and MtFRSt/F-AMS2) (Figure 3,
Table 2). The former three structures illustrate the initial
tRNA recognition state, where the enzyme binds primar-
ily to the anticodon region, with only partial contacts with
D- and T-loops of tRNA. In these structures the electron
density for the acceptor end of tRNA is poorly defined and
cannot be modeled. The MtFRSt/F-AMS2 structure cor-
responds to the tRNA aminoacylation ready state, where
the complex of MtFRS with tRNAPhe is predisposed for
acceptance of the activated amino acid. MtFRSt/F2 and
MtFRSt/F-AMS1 are isomorphous and contain a single
 unit in the asymmetric unit (ASU), while MtFRSt/F1
and MtFRSt/F-AMS2 have an entire ()2 heterotetramer
in the ASU of different unit cells. The crystal lattice or the
tRNA binding status do not seem to affect the protein in-
teractions with L-Phe, F-AMS and tRNA ligands.
Our findings are consistent with earlier observa-
tions, which indicate that the presence of adenylate
improves order of the CCA3′ end in crystal structures of
TtSRS/tRNASer complexes and the binding specificity
of E. coli tRNAHis to cognate EcHRS is increased when
adenylate analog 5′-O-[N-(L-histidyl)sulfamoyl]-adenosine
is bound to the active site (48,49). Interestingly, the
MtFRSt/F1 complex is reminiscent of other aaRS struc-
tures where the tRNA anticodon is properly recognized,
but the acceptor stem remains disordered, in particular
KRS–tRNALys complex (50) and the heterologous complex
composed of yeast tRNAAsp and E. coli DRS (51).
The structures of enzyme with specific MttRNAPhe show
the previously described tetrameric assembly (Figure 3).
The electron density for protein, tRNA, L-Phe, F-AMS is
excellent and with a few exceptions, as discussed earlier and
below, the entire structure can be modeled. The ()2 as-
sembly has a complex shape that can fit into a rectangular
prism with overall dimensions 70 Å × 110 Å × 170 Å. The
individual subunits are composed of several domains, which
structurally and functionally make sense only when assem-
bled into highly intertwined heterotetramer of this intricate
molecular machine. Each tRNA molecule interacts with all
four polypeptide chains.
Our high-resolution structures allow us to improve do-
main assignment and their boundaries. The smaller  sub-
unit (modeled residues 3–341) is very extended (∼130 Å)
and has two distinct domains, 1 and 2, connected by a 14-
residue linker (Figure 4, Supplementary Figure S3). The N-
terminal all helical 1 domain binds the tRNA D-loop re-
gion and the C-terminal 2 domain performs aminoacyla-
tion. The larger  subunit (modeled residues 1–831) can be
subdivided into three globular domains 1–3, two of which
have subdomains (Figure 4, Supplementary Figure S3). 1
has four distinct subdomains: 1s1, 1s2 and 1s3 corre-
sponding to the editing domain that shares fold with 2
catalytic domain (CATH domain 3.30.930.10), and 1s4.
The latter, a small / subdomain together with 1s1, inter-
acts with the 2 aminoacylation domain via direct protein-
protein contacts and a conserved magnesium ion. The 1s1,
1s3 and 1s4 subdomains form a core of 1 and 1s2
is on its periphery. 1s4 is followed by a 13-residue linker
connecting to the 2 domain, which consists of two subdo-
mains – larger 2s1 and smaller 2s2. 2 interacts exten-
sively with aminoacylation domain 2 (surface area ∼2150
Å2) contributing significantly to the complex interface. 2,
via a 15-residue linker, leads to the C-terminal domain 3
that extends out of the main body of the protein and is re-
sponsible for tRNA anticodon binding.
MttRNAPhe structure
The complete MttRNAPhe molecules are modeled only in
the MtFRSt/F-AMS2 complex, where the only atoms miss-
ing from the model correspond to the linkage between U21
and G22. Notably, this structure has been determined at
high magnesium concentration and several Mg2+ ions have
been identified––some of them are highly hydrated and bind
exclusively to the nucleic acid via electrostatic interactions
rather than direct metal ion coordination. The complete
structure of MttRNAPhe is similar to the partial structure of
the MttRNAPhe in the initial recognition structure (see be-
low) and other structures: the mature yeast equivalent car-
rying the Y base in the anticodon region (PDB id 4TNA),
unmodified T. thermophilus tRNAPhe transcript in complex
with FRS (PDB id 2IY5) and unmodified tRNAPhe tran-
script from E. coli (PDB id 3L0U). Sequence identity of
these tRNAs varies between 45 and 60% and their superpo-






/nar/advance-article/doi/10.1093/nar/gkab272/6246400 by guest on 28 April 2021
Nucleic Acids Research, 2021 7
Figure 1. MtFRS activity. (A) Aminoacylation of unmodified M. tuberculosis tRNAPhe. The 3′-32P-labeled tRNA transcript was charged with L-Phe in
the presence of purified MtFRS. The extent of aminoacylation was analyzed according to Varshney et al. (37). Prior to polyacrylamide gel electrophoresis,
tRNA and Phe-tRNA were digested with RNase T1 to yield 3′-32P-labeled CCACCA and CCACCA-Phe, respectively. (+) and (-) indicate the presence
and the absence of the enzyme. (B–D) Synthesis of the Phe-AMP intermediate by MtFRS in the presence of unmodified M. tuberculosis tRNAPhe (B), E.
coli tRNAPhe (C) and yeast tRNAPhe (D). Phe-[32P]AMP synthesis was monitored by thin layer chromatography. Phe-AMP and ATP denote 32P-labeled
compounds. F – full reaction; -E, -tRNA and -Phe – control reactions lacking the enzyme, tRNA or amino acid.
ranges between 2.3 and 3.2 Å, with the largest differences
observed for MttRNAPhe and TttRNAPhe. There is one
magnesium site in the D-loop region conserved between
yeast, E. coli and MttRNAPhe. As expected, the largest dif-
ferences are in the 3′ and 5′ ends, anticodon, T- and D-loops.
Some of the differences may result from the fact that we
compare free tRNA (E. coli and yeast) with tRNA bound
to protein (M. tuberculosis and T. thermophilus). In fact, an-
ticodon region of these last two tRNAs are more similar to
each other. The anticodon loop after the U33 base forms a
canonical U-turn stabilized by an internal hydrogen bond
of U33 N3 to phosphoryl group of A36 and 2′OH to N7
of A35. This element is conserved in all four structures. In
MttRNAPhe, six consecutive purine bases in the anticodon
region (G34 to G39) stack together and form a rigid struc-
ture important for tRNA recognition (see below), while E.
coli, T. thermophilus and yeast tRNAs have a block of five
stacked purine bases. Majority of bases are involved in base-
pairing/stacking, but curiously a number of bases project
into solvent in different tRNAs and they correspond to this
same RNA regions. For example: C17, U20, U47 (M. tuber-
culosis), U20, U45 (E. coli), D17, U47 (yeast), U17, U47 (T.
thermophilus). These structural features must be conserved
for functional reasons.
Ligand binding
The active site of FRS adenylation domain of the  subunit
contains subpockets responsible for recognition of L-Phe
and ATP substrates. Our structures illustrate how L-Phe
and its adenylate analog bind to their respective sites (Fig-
ure 5). In the phenylalanine-dedicated subpocket (Figure 5),
Phe255, Phe257, Ala305, Arg201, and Thr258 inter-
act with the aromatic ring of the ligand in both MtFRSt/F1
and MtFRSt/F2 structures. Arg201 and Gln215 form
hydrogen bonds with the carboxyl group while the amino
group is bonded to His175 and, via a water molecule,
to Gln215 and Glu217. The latter residue participates
in an extended network of hydrogen bonds which, besides
Gln215, includes Ser177 and Gln180. The organization
of the amino acid binding subpocket is virtually identical
in both tRNA-enzyme structures complexed with L-Phe.
However, in the neighborhood that does not directly par-
ticipate in the amino acid recognition, the conformations of
some side chains facing the adenine binding site differ be-
tween the two structures, and MtFRSt/F2 contains Mg2+
ion bound nearby the pocket, interacting with Glu263,
Glu279 and a water molecule. The adenine subpocket, in
the absence of a biological ligand, is occupied by a glycerol
molecule.
An analogous pattern of interactions with pheny-
lalanyl portion of the F-AMS ligand is observed in the
MtFRSt/F-AMS1 and MtFRSt/F-AMS2 complexes. Ad-
ditional bonds are formed with sulfamoyl group, ribose
and adenine moieties. The former interacts with the guani-
dinium group of Arg201 and via a water molecule with
Glu263 while the sugar ring forms hydrogen bonds with
Gln215, main chain carbonyl oxygen atom of Trp280
and carboxyl group of Glu279 (in chain A of MtFRSt/F-
AMS2). The nucleotide base is anchored between His209
and Phe213 and participates in several hydrogen bonds:
(i) N1 with main chain nitrogen atom of Thr210, (ii) N3
via a water molecule with main chain of Arg312 and
His214, and side chain of Glu311, (iii) N7 with Arg201
and Asp203 via another molecule and (iv) N6 with main
chain carbonyl group of Thr210 and carboxyl group of
Asp203. Most of these interactions are conserved between
the two F-AMS complexes, regardless of the tRNA binding
status, with the exception of Glu279, Glu263 and N7-
mediated contact.
The conformation of 2 domain is susceptible to the type
of ligand, as clear rearrangements are observed when L-
Phe and F-AMS complexes are compared. Specifically, in
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Figure 2. Inhibition of MtFRS by F-AMS. (A) Competitive binding of inhibitor with respect to L-Phe. Inhibitor concentrations were as follows: 0 M
(black line), 15 nM (green line), 50 nM (red line), and 125 nM. (B) Phe-[32P]AMP synthesis in the presence of 15 nM inhibitor (corresponding to green
line) monitored by thin-layer chromatography. The rate of Phe-[32P]AMP formation was determined at 37◦C over 10 min. (C, D) Competitive inhibition
of MtFRS by the F-AMS shown in the form of a Lineweaver–Burk plot. Km for Phe is 1.78 M (C). The secondary diagram was used to determine the
inhibition constant Ki, which is 33 nM (D). (E) Plot of the dose-response curve shows the percentage of initial velocity reduced by various concentrations
of the F-AMS. The insert illustrates the inhibition of Phe-[32P]AMP synthesis monitored by thin layer chromatography. Dotted lines indicate that the
inhibitor has IC50 value of ∼36 nM.
ements from the 4↑5↓9↑ 8↓7↑6↓ sheet moves to-
wards the 8↓7↑6↓ half, closing over the nucleotide moi-
ety. This movement enables His209 and Asp203 to ap-
proach the F-AMS base ring (Figure 5). The 8↓7↑6↓
section, especially the 7-8 hairpin, also comes closer
to the 4–5 loop. Similar conformational changes upon
binding of an adenylate analog were observed for other
aaRS, for example T. thermophilus KRS (50).
Initial tRNAPhe recognition
In the assembly, each of the tRNA molecules contacts all
four subunits through mostly 1′and 3′ domains and to
a lesser extent 2, 1 and 2. Remarkably, tRNA recog-
nition is accomplished by one  (purple/grey) unit while
aminoacylation and editing are completed by the comple-
mentary ’’ (coral/teal) dimer (Figure 3). In three struc-
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Figure 3. Overall structure of the MtFRS-tRNAPhe complex. (A) MtFRS-tRNAPhe heterotetramer with initial tRNA binding (MtFRSt/F1) (B) MtFRS-
tRNAPhe heterotetramer with the tRNA in aminoacylation ready state (MtFRSt/F-AMS2). Subunits  shown in purple and coral, subunits  shown in
gray and teal, tRNA represented as yellow and green ribbon models.
dent /tRNA structural representations), we observe the
initial recognition state. Here the anticodon-, D- and T-
stem and loop regions of tRNA are well-ordered. On the
other hand, the 3′ and 5′ ends of tRNA are disordered and
consequently only 5–69 tRNA bases could be modeled. In
these structures, access to the aminoacylation site is blocked
by the 310-helix region of the 2 domain (residues 152–157,
discussed below).
The tRNA selectivity is accomplished by enzyme inter-
acting with the anticodon region of tRNAPhe via anticodon
binding domain 3′ (Figure 6). In MttRNAPhe there is
a rigid six-purine stack (involving G34 to G39, three of
which constitute anticodon triplet (an identity element))
seems to be the key structural feature recognized by protein
that provides a shallow surface with several specific contact
points. The conserved ’Phe780 (FRSs have either pheny-
lalanine or tyrosine in this position) interact via – stack-
ing with the G34 guanine wobble anticodon base, extend-
ing the GAAAAG RNA stack. In addition, G34 forms sev-
eral direct hydrogen bonds. Specifically, ’Asp778 hydrogen
bonds to G34 N1 and N2, ’Arg830 to O6 and N7, and
’Gln784 interacts with G34 phosphoryl group or ribose
ring oxygen atom (observed in two structures of the initial
recognition state). Both ’Asp778 and ’Arg830 are highly
conserved residues. There are two direct hydrogen bonds to
A35, one from ’Ser747 to N6 and second from ’Thr793 to
N1. A36 interacts with the carboxylate group of conserved
’Asp745 via ribose 2′OH. The A37 ribose 2′OH also inter-
acts with ’Asp745.
The purine stack may represent a new recognition ele-
ment in tRNAPhe (E. coli and yeast tRNAsPhe have an equiv-
alent five-purine stack G34-A38) that is necessary for en-
hancing its binding specificity to cognate aaRSs. Because
position 39 is occupied by uridine in almost all known
tRNAPhe, which has much lower propensity for stacking
than purines, the role of the motif formed by stacked nu-
cleotides 34 through 38–39 has had been overlooked un-
til now. The stacking of the nucleotides 34–39 in tRNAPhe
molecules may play pivotal role in indirect readout of an-
ticodon stem-loop structure (52). This possibility was first
recognized when the crystal structure of the E. coli QRS–
tRNAGln complex was determined (53,54).
The interactions with D-loop vary across all three struc-
tures in the initial tRNA recognition state, indicating the
dynamic nature of these contacts. Here, the 1′ domain par-
ticipates in hydrogen bonds to G19 and/or U20 via ’Arg45
and/or ’Arg56, ’Asp37. Inconsistent pattern of interac-
tions is also present in binding with the T-loop. This re-
gion primarily implicates 1′Asn64 residues and, in some
instances, 1′Ala57 and/or 1′Arg45 that form hydrogen
bonds with C56 and G57.
tRNAPhe binding in preaminoacylation complex
In the MtFRSt/F-AMS2 structure, corresponding to
the tRNA aminoacylation ready state, the entire tRNA
molecule is ordered with the anticodon region firmly bound
and the acceptor arm approaching the active site contain-
ing the F-AMS–a phenylalanine adenylate analog (Figure
6). In this state, the enzyme continues to interact with the
anticodon region via domain 3′, maintaining all inter-
actions described above for the initial tRNA recognition
state. D-loop G19 and U20 bind to the 1′ domain with
somewhat different patterns. For example, G19 contacts a
coiled-coil extension in the enzyme’s -subunit, but con-
tacts with the D20 identity determinant are not visible (55).
Interestingly, photoaffinity cross-linking studies by Moor
et al. (56) demonstrated that contacts between D20 and -
subunit take place in TtFRS/tRNAPhe complex. Therefore,
our present studies of MtFRS and earlier studies of TtFRS
suggest that subtle structural perturbation occur in these
enzymes during aminoacylation. The T-loop is engaged as
described for the initial tRNA recognition state and variable
loop contributes one stabilizing interaction via the G45-
’Thr32 hydrogen bond.
Additional new features are observed as well. For exam-
ple, the phosphoryl group of A37 interacts with two cations.
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Figure 4. MtFRS domains. (A) Subunit . (B) Subunit . (C) Do-
main boundaries with starting residues numbered above the sequence-
representing bars and ending residues shown under the bars. Gray sections
depict linkers.
the other binds to ’Phe743 and two water molecules. This
latter region bridges the anticodon loop with the D-loop
arm, as the magnesium-coordinating water molecules and
’Phe743 main chain amide group bind to phosphoryl
group of G26. The 3′Glu807 main chain interacts with
the phosphoryl group of C25, and C25 with G24 2′OH
groups interact with main chain carbonyl oxygen atoms of
’Ala741 and ’Leu805. Additional hydrogen bonds link
’Pro738 to 2′OH of C11 and ’Thr804 to G24, with the
latter OG1 – N2 interaction being the only one involving a
D-loop base. Then, three hydrogen bonds connect the back-
bone of D-loop (G10, C11 and U12) to the 2s1 subdomain
(Ser578 and Arg579). All the contacts with the D-loop
arm (G10, C11, U12, G24, C25) exist only in the tRNA
aminoacylation ready state.
The most significant structural change, besides tighter
contacts with the D-loop arm, is the stabilization of the ac-
ceptor arm and 3′ end. This region becomes ordered and the
CCA3′ motif is inserted into acylation site, as observed for
other aaRS/tRNA complexes (57,58). This is possible be-
cause the 2 domain rearranges (Figure 6). Specifically, the
310-helix 2 and its short flanking sections (residues 151–
159) unfold into a loop-like structure. Residues Gln158,
Glu157 and Asp159 in the CCA3′ binding site dramati-
cally change their positions away from the pocket providing
access to the otherwise blocked active site. Thus, this sec-
tion of the protein serves as a 3′ end gate. Another residue
that moves significantly is His152, which relocates closer
to the binding pocket. There are two consequences of these
shifts––the first movement, particularly that of Asp159,
creates a new magnesium binding site and interacts with
A76, while the second positions His152 for the interaction
with the tRNA backbone.
The very well-ordered magnesium ion is hexagonally co-
ordinated by five water molecules and the carboxyl group
of Asp203. The water molecules bridge the protein and
the tRNA 3′ end, as they interact with Thr202, Gln158
(main chain), Asp159 (main chain and side chain) as well
as all three CCA bases. This rich network of water-mediated
contacts appears to be crucial for tRNA anchoring in the
active site as there are only two direct hydrogen bonds con-
tributing to the binding: A76 phosphoryl group interacts
with His152 and its purine N6 atom binds to the Asp159
main chain. The magnesium ion might be therefore essential
for proper positioning of the A76 ribose, which approaches
the imino moiety of the ligand within the 3.0 Å distance
of nitrogen atom to 2′OH. The observed geometry between
the acyl donor (F-AMS) and acceptor (tRNA), seen for the
first time for any aaRS-tRNA complex, mimics the reac-
tion stage where the 2′OH attacks the carbonyl carbon atom
and is fully consistent with the accepted mechanism for FRS
(59,60).
MtFRS vs other bacterial homologs
FRS homologs from E. coli (EcFRS), Staphylococcus
haemoliticus (ShFRS), P. aeruginosa (PaFRS), and the
most extensively studied from T. thermophilus (TtFRS)
have been characterized structurally as functional heterote-
tramers (Table 1). Overall organization of these proteins is
identical to that of MtFRS, however superpositions of the
entire chains lead to high RMSDs due to the movements of
the individual subdomains.
Several features of the adenylation active site are com-
mon between the four proteins. In particular, the residues
interacting with the L-Phe or adenylate ligands are mostly
conserved and superpose well, especially in the vicinity of
the amino acid moiety. The exceptions include His175 sub-
stitution by Gln169 in EcFRS associated with a differ-
ent conformation of the L-Phe ligand and inhibitor-induced
adjustments to the equivalents of Gln180 in ShFRS and
PaFRS. The region binding the nucleotide is less aligned.
Interestingly, the reorganization of the 2 domain upon
adenylate binding vs L-Phe binding varies between the ho-
mologs. While in EcFRS, PaFRS, and ShFRS the confor-
mation of ligand binding fragment of the 2 domain ap-
pears to follow the MtFRS pattern, being a more compact
in the presence of a nucleotide (E. coli) and an open without
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Figure 5. MtFRS interactions with ligands. (A) L-Phe binding to the aminoacylation site of FRSt/F1. The upper-left insert shows 2mFo-DFc electron
density map contoured around L-Phe at 1.2 . (B) Stereoview of F-AMS binding to the aminoacylation site of FRSt/F-AMS2. (C) Superposition of the
aminoacylation site of FRSt/F-AMS2 (purple), FRSt/F-AMS1 (yellow), and FRSt/F1 (coral). (D) F-AMS ligand and its 2mFo-DFc electron density
map from the FRSt/F-AMS2 complex contoured at 1.2 . Red spheres represent water molecules, a green sphere marks magnesium ion. Hydrogen bonds
are shown as dashed lines.
nounced in TtFRS. A small shift is only observed in the 4–
5 loop, the 8↓7↑6↓ subsection of the central -sheet
remains intact (Figure 7). The structure is not much differ-
ent when TtFRS is in complex with adenylate and tRNA.
The editing domain, encompassed within the 1s4 sub-
domain, also bears high level of similarity (Figure 6). The
residues lining the amino acid binding pocket, MtHis275,
MtLeu300, MtGly325, MtGlu344 and MtPro273
are conserved in TtFRS, EcFRS, PaFRS, and ShFRS.
MtGly324, MtMet327, MtAla366 and MtTyr370 are
sometimes replaced by similar residues (Supplementary
Figure S2). The most striking difference is the presence of
MtTrp348. This residue is unique to the M. tuberculosis
homolog, all other FRS contain Phe in this position. The
indole nitrogen atom is perfectly positioned to form a hy-
drogen bond with the ligand, possibly switching the amino
acid recognition from repulsive to attractive interactions
and providing distinct opportunities for selective inhibitors
targeting the editing domain.
T. thermophilus is the only homolog allowing for com-
parisons of the tRNA binding. The anticodon recognition
is achieved by binding to the 3′ domain, but the inter-
actions with tRNA vary between the two proteins due to
sequence variations. Mt’Ser747 and Mt’Thr793 are re-
placed by alanine residues (Tt’Ala698 and Tt’Ala744,
respectively), leading to the loss of direct hydrogen bonds
to A35 and a potential (water molecules are not mod-
eled in the TtFRSt structures) water-mediated contact with
G34. Alanine residues in these positions are more com-
mon in homologs than Thr and Ser (Supplementary Fig-
ure S2). Additional hydrogen bond bridging to the RNA
backbone is eliminated by another non-conserved sub-
stitution Mt’Gln784/Tt’Pro735. Residues Mt’Asp745,
Mt’Phe777, Mt’Asp778 and Mt’Arg830 are conserved
(Tt’Asp696, Tt’Phe728, Tt’Asp729 and Tt’Arg780)
and bind the tRNA molecule, albeit in somewhat differ-
ent fashion, and Tt’Tyr731 stacks against G34 similarly
to Mt’Phe780.
In the two TtFRS structures of complexes with tRNA,
the 3′ end appears to be inserted into the active site of the
acylation domain. However, neither of the modeled states
illustrate the reaction-ready position of the tRNA molecule
observed in MtFRSt/F-AMS2. In the TtFRS/tRNAPhe
complex, the 3′ end adenine moiety occupies the adeny-
late binding pocket, it is of note, however, that the elec-
tron density map for the acceptor arm is poor and there-
fore the accuracy of the model raises some concerns. In the
TtFRS/tRNAPhe/adenylate structure, the 3′ end adenosine
nucleotide faces the solvent. In neither of the TtFRS struc-
tures, the region equivalent to the 3′ end gate is significantly
reorganized to facilitate tRNA binding. It thus suggests that
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Figure 6. MtFRS interactions with tRNA. (A) tRNA sequence and molecule with interacting residues in MtFRSt/F-AMS2. (B) tRNA molecule and its
contacts with the polypeptide chain as seen in MtFRSt/F-AMS2 (chain C). The interacting residues include those forming hydrogen bonds, participating
in base/amino acid pairs and base/amino acid stacks, as defined by the SNAP program (http://forum.x3dna.org/dna-protein-interactions/). The C atoms
of the interacting residues are shown, colored as in A. Magnesium ions are colored green. Nucleotides have the following color-coding: G-purple, C-pink,
A-green, U-orange. (C) Stereoview of MtFRS interactions with the anticodon loop. (D) F-AMS (gray), tRNA 3′ end (green) and magnesium ion (green
sphere) binding in the MtFRSt/F-AMS2 active site shown in 2mFo – DFc electron density map contoured at 1.2 . (E) tRNA 3′ end interactions in
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Figure 7. Comparison of MtFRS with T. thermophilus FRS. (A, B) Comparison of the anticodon binding between MtFRSt/F-AMS2 (green, chain C/E)
and TtFRSt/adenylate (yellow, PDB 2IY5). In (A) ribbon representation of the 3′ domain and anticodon loop. In (B) atomic representation of the anti-
codon loop and interacting residues. For superposition only domain 3′ was used. Labels in black correspond to MtFRS, in yellow to TtFRS. (C) Super-
position of the aminoacylation domains from MtFRSt/F (coral), MtFRSt/F-AMS1 (blue), TtFRS/F (grey, 1B70), and TtFRS/adenylate (green, 1B7Y).
Only select residues are labeled. Parentheses indicate TtFRS. (D) Superposition of the 3′ end binding region in MtFRSt/F-AMS2 and TtFRSt/adenylate.
MtFRS is shown in purple (protein), green (tRNA) and grey (F-AMS). TtFRS is shown in yellow. (E) As in (D) but with the TtFRSt complex (pink).
Labels in black correspond to MtFRS, in yellow or pink to TtFRS. (F) Superposition of the editing domains (1s4 subdomain) from MtFRSt/F-AMS2






/nar/advance-article/doi/10.1093/nar/gkab272/6246400 by guest on 28 April 2021
14 Nucleic Acids Research, 2021
preventing the proper positioning of CCA3′ end. Of note,
while the 2 sequence is conserved in FRSs, the following
three amino acids are not: MtFRS contains the GEQ seg-
ment (residues 156–158) while TtFRS has DMW. It is not
only folded differently, but also is positioned closer to the
ligand binding pocket, with Trp149 facing the lumen and
overlapping with the 3′ end adenine of tRNA. Another fea-
ture distinct for TtFRS is the replacement of MtAsp203
with TtGlu206, indicating that the potential magnesium
binding site created during the aminoacylation reaction
may look somewhat different. In other bacterial homologs
the sequence of 3′ end gate region varies and adopts ei-
ther the TtFRS state (EcFRS) or MtFRSt/F-AMS2 state
(StFRS, PaFRS). While they preserve Asp corresponding
to MtAsp203, neither binds a metal cation in the magne-
sium site. Given the lack of any obvious common patterns
guiding the conformation of the 3′ end gate, such as the
tRNA presence, magnesium coordination, ligand binding
or sequence motifs, it appears that its state might be gov-
erned by cellular conditions these enzymes must function
in.
MtFRS versus human FRSs
Humans have two FRSs, cytoplasmic (hcFRS) and mito-
chondrial (hmFRS), both of which have had their struc-
tures determined (Table 1). The hcFRS resembles MtFRS
()2 heterotetramer but it lacks the anticodon binding
domain and contains an extra domain in the  subunit.
The hmFRS variant, characterized in several states, includ-
ing heterologous complex with T. thermophilus tRNAPhe,
is a monomeric chimera of the bacterial 2 catalytic mod-
ule and anticodon binding domain 3. HmFRS exists in
two states: closed in the absence of tRNA, where the 3
domain blocks the access to 2, and open, which mim-
ics the domains arrangement seen in bacterial ()2 com-
plexes (11). While overall organization and sequences of
the human enzymes are distinct from MtFRS, the cor-
responding domains superpose well. The aminoacylation
domain of hmFRS adopts conformation similar to that
of MtFRSt/F-AMS2, with the 7-8 hairpin equivalent
closed over the pocket and the 3′ end gate open regardless
of the ligand/tRNA binding status. The cytosolic homolog,
characterized in the presence of L-Phe, remains more open,
as seen in the initial tRNA recognition complexes, with its
3′ end gate open as well.
The aminoacylation sites of the human enzymes,
especially hmFRS, share high similarity with MtFRS
(Figure 8). Several residues lining the adenylate binding
site are also conserved. In hmFRS the only exception
includes replacement of MtVal286, sitting deep in
the L-Phe pocket, by hmMet258. HcFRS is more vari-
able, with several substitutions in the L-Phe binding
site: MtPhe257/hcTyr412, MtPhe255/hcAsn410,
MtVal286/hcPhe438, MtGly282/hcAsn434, and
MtGln180/hcSer332. These residues are located in the
L-Phe binding cavity, which is generally better aligned
between the homologs than the adenine-dedicated pocket.
The editing domain of hcFRS is differently organized in
terms of the secondary structure composition, and conse-
quently some of the residues lining the cavity come from
different structural elements than in MtFRS, making the
architecture of this site substantially different. In particular,
the side chain of MtTyr370 is in three-dimensional context
replaced by hcArg118 and the role of MtTrp348 is played
by hcThr256 and the surface created by MtAla366 is
lined with hcArg154. Also, some residues contributed
by analogous secondary structures differ: MtbHis275 is
replaced by hcGly160 while MtGly328 is mutated to
hcAsn238.
The tRNA anticodon interactions with hmFRS mostly
resemble those found in MtFRS including recognition of
the wobble base and the key residues are conserved or re-
placed by similar side chains (Mt’Thr793 to hmCys377 or
Mt’Phe777 to hmIle363). The hydrogen bond linking the
protein with the RNA backbone via Mt’Gln784 (replaced
by hmLys370) is eliminated due the conformational rear-
rangement of this protein segment.
Functional implications
All tRNAs must have similar shape to fit into ribosomal
translation machinery and have identical CCA3′ end to
deliver amino acid to the ribosome active site. The tR-
NAs seem to have common origin and have significant se-
quence conservation, as they were generated from repeat-
ing sequences and inverted repeats (6). During evolution
these tRNAs differentiated into over 20 amino acid specific
groups. It is believed that aaRSs emerged together with tR-
NAs and they coevolved, making aaRSs one of the oldest
enzymes to arise. Today’s aaRS utilize different scaffolds,
tRNA recognition strategies and catalytic mechanisms to
catalyze aminoacylation reaction. In bacteria, each enzyme
must specifically recognize tRNA(s) specific for a single
amino acid from a pool of some 30 plus tRNAs.
So how do aaRSs enzymes make the connection? The
amino acid specific isoacceptor tRNAs may have up to six
different codons and these tRNAs are aminoacylated by a
single enzyme. At the same time, amino acid must be de-
livered to adenosine ribose at 3′ end, about 65 Å away from
the anticodon. Therefore, for aaRSs codon recognition may
not be the easiest solution to accomplish this.
It was proposed that a code exists equivalent to the ‘ge-
netic code’ in the interactions between aaRS and tRNAs.
This code was linked to amino acid properties. One hypoth-
esis proposed that aaRS emerged first as ancestor urzyme-
like synthetase that initially recognized only the acceptor
stem and later evolved to include other parts of tRNA to
increase specificity. Urzymes correspond to conserved cores
of both classes of aaRSs lacking their anticodon-binding
domains. Surprisingly, urzymes catalyze amino acid activa-
tion and acyl transfer with affinities similar to full length
aaRSs (61). The argument for first aaRS to recognize tRNA
acceptor stems rather than anticodons is in agreement with
the idea that originally proteins were coded by an ‘opera-
tional RNA code’ located in the acceptor stem (62,63).
Structural studies of aaRS complexes with tRNA
showed, that there are two groups of enzymes, one that
recognizes both anticodon loop and stem to discriminate
between cognate and non-cognate tRNA and the other
that does not. Earlier studies of the yeast FRS binding to
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Figure 8. Comparison of MtFRS with human FRSs. (A, B) Superposition of the aminoacylation domains from MtFRSt/F-AMS2 (purple) with human
mitochondrial (hm) enzyme in complex with adenosine-5′-[phenylalaninyl-phosphate] (3CMQ, olive green) or with T. termophilus tRNAPhe, hmFRSt
(3TUP, coral). In (B), close-up view of the L-Phe subpocket is shown. (C, D). Superposition of the aminoacylation domains from MtFRSt/F-AMS2 (pur-
ple) with human cytosolic enzyme (hcFRS) in complex with L-Phe (3L4G, green). In (D), close-up view of the L-Phe subpocket is shown. (E) Superposition
of the anticodon binding region of MtFRSt/F-AMS2 (gray) and hmFRSt (coral). Labels in parentheses correspond to the respective human homologs.
(F) Superposition of the editing domains (1s4 subdomain) from MtFRSt/F-AMS2 (gray) and hcFRS (3L4G, green). Gold L-Tyr from the TtFRS/L-Tyr
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lectivity in positions 20, 34, 35, 36 and 72 (64), implying
that FRS belongs to the former category. Two codons code
for L-Phe, 3′CUU and 3′UUU, however typically only one
isoacceptor tRNAPhe with 5′GAA anticodon is required to
decode both of these two codons, as the wobble G base can
pair with both C and U. This is the case for M. tuberculosis,
as it has only one tRNAPhe. Our structures demonstrated
direct FRS interactions only with U20, G34, A35 and A36,
with U20 and A36 having very minor contributions. There-
fore, the role of A36 and A72 must be indirectly affect-
ing the structure of tRNA that allows it to make the other
interactions. Additional interactions are observed through
phosphate and sugar moieties. Interestingly, this pattern is
in good agreement with nucleotides characterized as iden-
tity determinants for aminoacylation of tRNAPhe by E. coli
FRS (65) where ten out of the eleven nucleotides (G10, U20,
G25, A26, G34, A35, A36, G44, G45, U59 and A73) are in-
volved in interactions.
Our data confirm the interaction of FRS with the an-
ticodon loop and stem, yet no anticodon sequence is rec-
ognized. The key feature of the initial detection is bind-
ing to the G34 wobble base, the least important in codon-
anticodon pairing. With the most extensive interactions
with 3′ domain residues G34 appears to be the primary
discriminator with some additional selectivity provided by
A35, A36, G19 and U20. We believe that the recognition of
the anticodon loop and stem is governed by the structural
motif of stacked five-six purine bases (six for M. tuberculo-
sis tRNAPhe, five for T. thermophilus tRNAPhe), which posi-
tions tRNA and FRS to make additional contacts, includ-
ing D- and T-loops. This interface is preserved across the
FRS family, including much simplified version of the en-
zyme found in human mitochondria. FRS does not interact
with the acceptor stem at all, in fact in the initial recognition
step the acceptor stem is disordered and the access to active
site is often blocked by the enzyme itself. Completion of the
recognition process allows for conformational changes in
the 3′ gate permitting binding of the CCA3′ region into the
active site.
It seems FRS lost its need to read the CCA stem sequence.
This is because other parts of tRNAPhe provide unique sig-
natures sufficient to allow FRS to distinguish it from other
tRNAs. FRS is a large, multidomain enzyme that provides
many opportunities for interactions and specificity. tRNA
molecules also offer a variety of surfaces for interactions.
Based on our results and earlier published data, we hypoth-
esize that recognition of the CCA stem might have been es-
sential for ancestral aaRSs to discriminate between tRNAs,
but later in the evolution of the protein genetic code, new
specificity determinants were added while previous were
lost. This indirect recognition in protein-nucleic acids inter-
actions is one of the most important highlights of biological
systems.
Therapeutics development
With a multidomain structure rich in pockets, equally com-
plex reaction and essentiality, FRS represents an important
target for drug discovery. Highlighted by our study struc-
tural differences between the active sites of bacterial and
human FRS could be exploited to design narrow spectrum
inhibitors that would have low toxicity for humans, other
animal hosts and their microbiomes. Admittedly, close sim-
ilarity of the adenylate binding cavity between MtFRS and
mitochondrial homolog presents a formidable challenge for
medicinal chemistry. Therefore, targeting the editing do-
main, substantially distinct from the cytoplasmic variant
and absent in the mitochondrial enzyme may offer an un-
tapped opportunity. We will pursue a drug discovery pro-
gram of MtFRS and plan to present our results in the future
manuscript.
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